Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +32.72%
#3 Cysic Cysic +24.17%
#4 Velvet Velvet +19.00%
#5 Bedrock Bedrock +17.15%
#6 Nockchain Nockchain +15.87%
#7 Nillion Nillion +15.42%
#8 Perle Perle +15.38%
#9 Fabric Protocol Fabric Protocol +14.59%
#10 Versatize Coin Versatize Coin +12.49%
Coin of the day
EXOD EXOD
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCI
Kedudukan dalam Saham #37527
Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998,... Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998, is a pharmaceutical company that focuses on the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage medications, primarily for the United States market. The company leverages its patented Hypermatrix technology to create advanced drug delivery systems, an array of product candidates, and a robust pipeline across diverse therapeutic areas, including neurological, cardiovascular, gastrointestinal, diabetes, and pain management conditions. Its current product portfolio includes extended-release formulations like Focalin XR for hyperactivity disorder, Keppra XR for partial onset seizures, Effexor XR to treat depression, and Protonix for gastroesophageal reflux disease. Other offerings feature Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and mood disorders, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. Furthermore, Intellipharmaceutics is actively developing additional controlled-release drugs such as OxyContin for pain relief and Regabatin XR for neuropathic pain management. The company operates under a license and commercialization agreement with Par Pharmaceutical Inc.
Harga Saham
$0.05897422
Disegerakkan terakhir: 2024-04-02
Modal Pasaran
$1.64M
Perubahan (1 hari)
0.07%
Perubahan (1 tahun)
0.00%
Negara
CA
Perdagangan Intellipharmaceutics International Inc. (IPCI)

Kategori

Healthcare
Nisbah P/E bagi Intellipharmaceutics International Inc. (IPCI)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Intellipharmaceutics International Inc., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Intellipharmaceutics International Inc. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.